Patents Assigned to Pharmacyclics, Inc.
  • Patent number: 9133202
    Abstract: Disclosed herein are compounds of Formula (A) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 13, 2013
    Date of Patent: September 15, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Patent number: 9133201
    Abstract: Disclosed herein are compounds of Formula (A) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 6, 2013
    Date of Patent: September 15, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Patent number: 9125889
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: July 31, 2014
    Date of Patent: September 8, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Patent number: 9128096
    Abstract: Described herein are methods and compositions for determining whether a particular cancer is resistant to or susceptible to a histone deacetylase inhibitor or to histone deacetylase inhibitors. The methods include analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are methods and compositions for increasing the likelihood of a therapeutically effective treatment in a patient, comprising an analysis of the expression levels of at least four biomarker genes associated with response to a histone deacetylase inhibitor. Also described herein are isolated populations of nucleic acids derived from a cancer sensitive to or resistant to a histone deacetylase inhibitor. Further described are kits and indications that are optionally used in conjunction with the aforementioned methods and compositions.
    Type: Grant
    Filed: October 5, 2010
    Date of Patent: September 8, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Sriram Balasubramanian
  • Patent number: 9127012
    Abstract: Disclosed herein are compounds of Formula (A) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: September 20, 2013
    Date of Patent: September 8, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Patent number: 9115108
    Abstract: Abexinostat tosylate of formula (II): and its crystalline form I characterized by its X-Ray powder diffraction diagram, its Raman spectrum and its solid-state 13C CP/MAS NMR spectrum. Medicinal products containing the same which are useful in the treatment of cancer.
    Type: Grant
    Filed: March 3, 2014
    Date of Patent: August 25, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Anne Pimont-Garro, Philippe Letellier
  • Patent number: 9107924
    Abstract: Described herein are irreversible Btk inhibitor compounds, and methods for using such irreversible inhibitors in the treatment of diseases and disorders characterized by the presence or development of solid tumors.
    Type: Grant
    Filed: August 12, 2013
    Date of Patent: August 18, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Joseph J. Buggy, Laurence Elias
  • Patent number: 9096604
    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: August 4, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • Patent number: 9079908
    Abstract: Described herein are irreversible kinase inhibitor compounds exemplified by the following structure Formula (B2): methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of a B cell proliferative disorder or a mast cell proliferative disorder.
    Type: Grant
    Filed: July 6, 2012
    Date of Patent: July 14, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen
  • Publication number: 20150184249
    Abstract: Described herein are mutations that confer resistance to treatment with a BTK inhibitor. Described herein are modified BTK polypeptides that exhibit decreased inhibition (i.e. are resistant) to a covalent and/or irreversible BTK inhibitor. Also described herein modifications of PLCy2 and CARD 11 polypeptides that confer resistance to treatment with a BTK inhibitor. Described herein are diagnostic methods for detecting the modified polypeptides and nucleic acids encoding the modified polypeptides and applications of the methods thereof. Described herein are compositions, combinations, and kits containing the modified polypeptides and methods of using the modified polypeptides. Also described herein are methods of using modified BTK polypeptides as screening agents for the identification and design of second-generation BTK inhibitors.
    Type: Application
    Filed: July 23, 2013
    Publication date: July 2, 2015
    Applicant: PHARMACYCLICS, INC.
    Inventors: Betty Chang, Joseph J. Buggy, Susanne M. Steccerda
  • Patent number: 9062058
    Abstract: Disclosed herein are compounds exemplified by the following structure Formula (I) that form covalent bonds with Bruton's tyrosine kinase (Btk). Also disclosed are pharmaceutical compositions that include the compounds of Formula (I). Methods of using the Btk inhibitors exemplified by the structure of Formula (I) are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: November 15, 2013
    Date of Patent: June 23, 2015
    Assignee: PHARMACYCLICS, INC.
    Inventors: Wei Chen, David J. Loury, Longcheng Wang
  • Publication number: 20150111912
    Abstract: Described herein are kinase inhibitor compounds, methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Application
    Filed: May 15, 2013
    Publication date: April 23, 2015
    Applicant: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody
  • Patent number: 9012463
    Abstract: Described herein are kinase inhibitor compounds of Formula IV: wherein Rb, R6, T, Y, and Z are defined herein. Also described herein are methods for synthesizing such inhibitors, and methods for using such inhibitors in the treatment of diseases. Further described herein are methods, assays and systems for determining an appropriate inhibitor of a protein, including a kinase.
    Type: Grant
    Filed: October 12, 2010
    Date of Patent: April 21, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Wei Chen, David J. Loury, Tarak D. Mody, Erik Verner, Mark Stephen Smyth, Wenchen Luo
  • Patent number: 8999999
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Grant
    Filed: January 22, 2013
    Date of Patent: April 7, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Patent number: 8987233
    Abstract: Described herein are probes for Bruton's tyrosine kinase (Btk). Such probes are used to characterize and develop Btk-selective inhibitors intended for therapeutic use.
    Type: Grant
    Filed: November 5, 2007
    Date of Patent: March 24, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Zhengying Pan, Shyr Jiann Li, Heleen Scheerens, Lee Honigberg, Erik Verner
  • Patent number: 8975266
    Abstract: Disclosed herein are pyrazolo[3,4-d]pyrimidines that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk. Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: March 22, 2013
    Date of Patent: March 10, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Patent number: 8957079
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure: Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: October 17, 2012
    Date of Patent: February 17, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Patent number: 8952015
    Abstract: Disclosed herein are compounds that form covalent bonds with Bruton's tyrosine kinase (Btk). Also described are irreversible inhibitors of Btk, such as those having the structure of Formula (A) Methods for the preparation of the compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the Btk inhibitors are disclosed, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions.
    Type: Grant
    Filed: October 19, 2010
    Date of Patent: February 10, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik Verner, Zhengying Pan
  • Publication number: 20150031710
    Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.
    Type: Application
    Filed: February 24, 2014
    Publication date: January 29, 2015
    Applicant: Pharmacyclics, Inc.
    Inventors: Joseph J. BUGGY, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
  • Patent number: 8940750
    Abstract: Described herein are irreversible kinase inhibitor compounds, methods for synthesizing such irreversible inhibitors, and methods for using such irreversible inhibitors in the treatment of a B-cell proliferative disorder or a mast cell proliferative disorder having the structure of Formula (A1)
    Type: Grant
    Filed: September 7, 2012
    Date of Patent: January 27, 2015
    Assignee: Pharmacyclics, Inc.
    Inventors: Lee Honigberg, Erik J. Verner, Joseph J. Buggy, David J. Loury, Wei Chen